Albany, NY -- (SBWIRE) -- 01/12/2018 -- An anus is surrounded by number of small glands. Whenever any gland gets blocked, it is converted into an abscess, also known as an infected cavity. The abscess can turn into a fistula if untreated for a long time. Anal fistulas are small tunnels connecting these infected glands inside the anus. Fistula can develop inside or outside the anus i.e., internal fistula or external fistula. The risk of developing fistula is higher after gestation, in Crohn's disease, infection, trauma, tuberculosis, cancer, or as a result of post-surgery complications.
According to the American Society of Colon and Rectal Surgeons (ASCRS), 50% of patients with abscesses experience anal fistula. Anal fistulas can reoccur despite proper treatment and healing of previous fistula. The rate of reoccurrence of anal fistula depends on type of surgery performed to cure it. Symptoms of anal fistula include irritation of the skin around the anus due to persistent drainage, recurrent anal abscess, pain and swelling around the anus, pain with bowel movements, bleeding, fever, chills, and a general feeling of fatigue. Increase in incidence of gastrointestinal conditions such as Crohn's disease, irritable bowel syndrome, and gastrointestinal cancers leading to the formation of anal fistulas is driving The Global Anal Fistula Diagnosis And Treatment Market. However, lack of awareness about available treatments in several developing countries restrains the market.
The global anal fistula diagnosis and treatment market can be segmented based on diagnostic devices, surgery performed, drug class, application, and region. In terms of diagnostic devices, the market can be categorized into X-ray, colonoscopy, anal ultrasound, fistulography, fistula probe, anoscope, flexible sigmoidoscopy, injected dye solution, and MRI. Based on surgery performed, the global anal fistula diagnosis and treatment market can be divided into fistulotomy, Seton techniques, advancement flap procedures, fibrin glue, bio prosthetic plug, and other emerging techniques. Fistulotomy dominates the global anal fistula diagnosis and treatment market due to high success rate. In terms of drug class, the market can be classified into laxatives, bulk-producing agents, psyllium, vasodilators, anxiolytics, benzodiazepines, antibiotics, calcium channel blockers, neuromuscular blockers, botulinum toxins, and pain medicines. Based on application, the global anal fistula diagnosis and treatment market can be segmented into extrasphincteric fistula, suprasphincteric fistula, transphincteric fistula, intersphincteric fistula, intersphincteric fistula, and submucosal fistula.
Request to View Brochure of Report -
Geographically, the global anal fistula diagnosis and treatment market can be segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominates the global market owing to increase in number of patients with Crohn's disease, technological advancements in anal surgeries, and presence of key players. Europe is the second largest market for anal fistula diagnosis and treatment, attributed to high adoption rate of minimally invasive surgeries, increase in number of patients diagnosed with anal fistula, and new product launches. For instance, according to the research published by the National Center for Biotechnology Information (NCBI), in 2014, the incidence rate of anal fistulas in four countries in Europe such as England, Germany, Italy, and Spain was between 12 and 28 per 100,000. The market in Asia Pacific is expected to expand at the highest CAGR during the forecast period due to rise in number of patients with Crohn's disease, gastrointestinal cancers, and irritable bowel syndrome in the region. Latin America and Middle East & Africa can be considered emerging markets due to growing health awareness, changing health care infrastructures, and increasing presence of key players.
Major players operating in the global anal fistula diagnosis and treatment market are Cook, Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Novartis AG, Ethicon, Inc., F. Hoffmann-La Roche Ltd, W. L. Gore & Associates, Inc., Boehringer Ingelheim GmbH, and Bristol-Myers Squibb Company, among others.
Pre-Book Full Report -